000			02130naaaa2200301uu 4500
001			https://directory.doabooks.org/handle/20.500.12854/65253
005			20220220085327.0
020			_a954
020			_a9789533074634
020			_a9789535165453
024	7		_a10.5772/954 _cdoi
041	0		_aEnglish
042			_adc
072		7	_aJMM _2bicssc
100	1		_aFinkelstein, David I. _4edt
700	1		_aFinkelstein, David I. _4oth
245	1	0	_aTowards New Therapies for Parkinson's Disease
260			_bIntechOpen _c2011
300			_a1 electronic resource (410 p.)
506	0		_aOpen Access _2star _fUnrestricted online access
520			_aParkinson's disease (PD) is characterised clinically by various non-motor and progressive motor symptoms, pathologically by loss of dopamine producing cells and intraneuronal cytoplasmic inclusions composed primarily of ?-synuclein. By the time a patient first presents with symptoms of Parkinson's disease at the clinic, a significant proportion of the cells in the substantia nigra have already been destroyed. This degeneration progresses despite the current therapies until the cell loss is so great that the quality of normal life is compromised. The dopamine precursor levodopa is the most valuable drug currently available for the treatment of PD. However for most PD patients, the optimal clinical benefit from levodopa decreases around five to six years of treatment. The aim of the chapters of this book is to work towards an understanding in the mechanisms of degeneration and to develop disease modifying therapies.
540			_aCreative Commons _fhttps://creativecommons.org/licenses/by/3.0/ _2cc _4https://creativecommons.org/licenses/by/3.0/
546			_aEnglish
650		7	_aPhysiological & neuro-psychology, biopsychology _2bicssc
653			_aPhysiological & neuro-psychology, biopsychology
856	4	0	_awww.oapen.org _uhttps://mts.intechopen.com/storage/books/437/authors_book/authors_book.pdf _70 _zDOAB: download the publication
856	4	0	_awww.oapen.org _uhttps://directory.doabooks.org/handle/20.500.12854/65253 _70 _zDOAB: description of the publication
999			_c77089 _d77089